Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Discovery Of A T Cell Proliferation-associated Regulator Signature Correlates With Prognosis Risk And Immunotherapy Response In Bladder Cancer

Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer

Ting Yan1, Wei Zhou2, Chun Li3

  • 1Department of Blood Purification Center, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, No.141, Tianjin Road, Huangshi, 435000, Hubei, People's Republic of China.

International Urology and Nephrology
|May 24, 2024

Related Experiment Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.5K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K

View abstract on PubMed

Summary
This summary is machine-generated.

This study identified two bladder cancer subtypes based on T cell proliferation regulators, predicting patient prognosis and immunotherapy response. A prognostic signature helps identify patients likely to benefit from treatment.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Immunotherapy efficacy is significantly influenced by T cell activity.
  • Understanding T cell proliferation regulators is crucial for predicting bladder cancer patient outcomes.
  • This study investigates the role of T cell proliferation regulators in bladder cancer (BCa) prognosis and immunotherapy response.

Purpose of the Study:

  • To characterize T cell proliferation-related subtypes in bladder cancer.
  • To develop a prognostic signature for bladder cancer patients.
  • To evaluate the predictive value of T cell proliferation regulators for immunotherapy response.

Main Methods:

  • Non-negative matrix factorization (NMF) identified T cell proliferation-related subtypes.
  • Prognostic and immune infiltration analyses were performed on identified subtypes.
Keywords:
Bladder cancerImmunotherapyPrognosisT cell proliferation

Related Experiment Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.5K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K
  • Cox and Lasso regression built and validated a prognostic risk model across multiple cohorts, including an immunotherapy cohort.

    • Main Results:

    • Two distinct subtypes (C1 and C2) were identified based on 31 T cell proliferation-related genes, showing different prognoses and immune landscapes.
    • Subtype C2 exhibited poorer overall survival, increased M2 macrophage infiltration, and activated cancer pathways.
    • A 13-gene prognostic signature predicted poorer outcomes, increased immunosuppression, and diminished immunotherapy response in high-risk patients.

    Conclusions:

    • Two T cell proliferation-linked subtypes in bladder cancer reveal distinct prognoses and tumor microenvironment patterns.
    • The identified prognostic signature offers clinical utility for predicting bladder cancer patient outcomes.
    • This signature may aid in selecting patients who will benefit most from current immunotherapy strategies.
    Tumor microenvironment